Skip to main content

Table 2 Clinical studies of the fixed combination of acetylsalicylic acid (ASA) + Paracetamol (PARA) and caffeine (CAF) (published 1988-2006)

From: Combined analgesics in (headache) pain therapy: shotgun approach or precise multi-target therapeutics?

Study

Study design

Indication

Results-efficacy endpoint

Bosse & Kühner 1988[57]

randomized double-blind, multicenter study

Headache of different genesis

ASA + PARA + CAF* > 250 mg ASA + 250 mg PARA

ASA + PARA + CAF* > 500 mg ASA

Migliardi et al. 1994[48]

four identical, randomized double-blind, two-period crossover, multicenter studies

Tension-type headache

ASA + PARA + CAF** > 1000 mg PARA

ASA + PARA + CAF** > Placebo

Lipton et al. 1998[58]

three randomized, double-blind, studies.

Migraine

ASA + PARA + CAF** > Placebo

Diener et al. 2005[59]

randomized double-blind, multicenter study

Migraine and tension-type headache

ASA + PARA + CAF*** > 500 mg ASA + 400 mg PARA

ASA + PARA + CAF*** > 1000 mgASA

ASA + PARA + CAF*** > 1000 mg PARA

ASA + PARA + CAF*** > 100 mg CAF

ASA + PARA + CAF*** > Placebo

Goldstein et al. 2005[60]

randomized double-blind, multicenter study

Migraine

ASA + PARA + CAF** > 50 mg Sumatriptan

ASA + PARA + CAF** > Placebo

Goldstein et al. 2006[61]

randomized double-blind, multicenter study

Migraine

ASA + PARA + CAF** > 400 mg Ibuprofen

ASA + PARA + CAF** > Placebo

  1. *: 250 mg ASA + 200 mg PARA + 50 mg CAF; **: 500 mg ASA + 500 mg PARA + 130 mg CAF; ***: 500 mg ASA + 400 mg PARA + 100 mg CAF.